Patients 18 years or older with R/R DLBCL who received at least 2 prior lines of therapy (de novo DLBCL or from transformed FL, and high‐grade B‐cell lymphoma with MYC rearrangement plus rearrangement of Bcl2, Bcl6 or both). This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.